Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time
Rhea-AI Summary
Senseonics (NASDAQ: SENS) will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern Time the same day, accessible via the company’s Investor Relations website and by phone using the provided dial-in numbers and passcode.
Positive
- None.
Negative
- None.
News Market Reaction – SENS
On the day this news was published, SENS declined 1.57%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 10 | Partnership announcement | Positive | -1.8% | Partnership announced to develop a next-generation Eversense 365 mobile application. |
| Jun 06 | Clinical evidence presentation | Positive | +5.2% | Real-world Eversense 365 evidence showed adherence and one-year performance across use cases. |
| Jun 01 | Analyst event notice | Neutral | +0.7% | Company scheduled an analyst event and oral presentation of Eversense 365 performance data. |
| May 07 | Quarterly earnings report | Positive | -6.2% | First-quarter results included revenue growth, financing activity, and raised full-year guidance. |
| May 04 | Public offering closing | Negative | -0.2% | Underwritten offering closed with common shares and pre-funded warrants issued. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Reactions were mixed: the prior earnings release fell 6.16%, while a real-world-evidence presentation rose 5.17%.
Key Terms
continuous glucose monitoring medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026.
Management will hold a conference call to review the Company’s second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-833-354-6854 (US/Canada) or 1-785-838-9343 (International), passcode SENSQ2, approximately ten to five minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development, manufacturing and commercialization of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
